[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tampere Heart Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":5},"100627153","validation-of-sudden-cardiac-arrest-risk-factors-in-patients-with-cad-100627153",false,"NCT07444931","Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD","Validation of Sudden Cardiac Arrest Risk Factors in Patients With CAD - CVDLINK Clinical Validation Study.","SCAR","Inclusion Criteria:\n\n* Age ≥ 18 years old\n* Ability to give informed consent\n* Imaging confirmed diagnosis within the past 12 months (coronary artery angiography or contrast enhanced coronary computed tomography)\n\n  •\\>50% of stenosis and\u002For fractional flow-reserve \\\u003C0.8 verified by selective coronary angiography or by contrast enhanced coronary computed tomography (CT) or type I MI with atherosclerotic origin (despite stenosis percentage)\n* Patients may be recruited during index event visit (out-patient clinic visit, invasive procedure, hospitalization) (or if logistically possible recall patients previously diagnosed within 12 months)\n\nExclusion Criteria:\n\n* Age \\> 75 years of age\n* Clinically significant previously treated valvular heart disease or requiring operative (surgical or endovascular) treatment within following three months\n* Diagnosed severe neurodegenerative disease (ALS, myositis, multiple sclerosis, or Parkinson's disease) or known impaired cognitive function (MMSE \\\u003C23)\n* Known developmental disability impairing legal ability to give written consent\n* Serious\u002Factive malignancy with possibly reduced life expectancy of \\\u003C1 year (estimated by a physician)\n* Inability to give written consent for some other reason\n* Other significant cardiac condition severely linked to the risk of fatal ventricular arrhythmia (for example ARVCD, non-ischemic DCM, HCM or genetic long or short QT syndrome)\n* Other cardiac disease with \\\u003C1 years of life expectancy\n* Do-Not-Resuscitate (DNR) order made due to any reason\n* Previously done or planned cardiac, renal, or liver transplant\n* Participation in another clinical trial where the active treatment","ALL","18 Years","75 Years",{"count":21,"type":22},1500,"ESTIMATED","1 Year","OBSERVATIONAL","Long-term sudden cardiac death (abbreviation: SCAR) focuses on improving the predictability of sudden cardiac death (SCD) in patients diagnosed with coronary artery disease. The aim of the study is to determine the predictive value of measurable biological variables (including genetic factors, cardiac electrical activity, biological markers measured from circulation, and coronary artery anatomy) as well as the patients' psychosocial factors in predicting SCDs.\n\nThe purpose of this study is the identification of a subgroup of coronary artery disease patients at sufficiently high risk in whom it may be possible to prevent sudden cardiac arrests and subsequent deaths using implantable cardioverter-defibrillators. The study is intended to establish a clear foundation for future interventional studies targeting high-risk coronary artery disease patients.\n\nThe primary endpoint of the study is SCD\u002Fsudden cardiac arrest (SCA) or a comparable malignant arrhythmic event (i.e., resuscitation). Secondary endpoints include other major cardiovascular events occurring during the follow-up period (such as cerebrovascular events, myocardial infarctions, revascularizations, and new arrhythmias like atrial fibrillation following procedures or after the patient has been discharged following recruitment) or the occurrence and mortality of other significant life-threatening diseases (such as cancer). Secondary endpoints also include poor success in secondary prevention, which can be assessed through completed medication purchases and the achievement of secondary prevention goals.\n\nThis observational, prospective study includes collecting multimodal data from hospitals in Finland (TAUH), Israel (HYMC), Moldova (IMSP) and Romania (UMFCD). Each participating institution has followed a process structured by Tampere Heart Hospital (TAUH) for securing permissions in line with EU and national regulations.",[27,28,29],"Coronary Arterial Disease (CAD)","Sudden Cardiac Arrest","Sudden Cardiac Death",[31,32,33,34,35,36],"Coronary artery disease","Sudden cardiac arrest","Sudden cardiac death","post operative atrial fibrillation","genetics","risk factors","RECRUITING","2026-03-02",{"date":40,"type":41},"2026-03-03","ACTUAL",{"date":43,"type":41},"2025-01-05",{"date":45,"type":22},"2027-12-31",{"name":47,"class":48},"Tampere Heart Hospital","OTHER",{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100577886","exercise-based-rehabilitation-in-patients-with-pulmonary-arterial-hypertension-100577886","NCT06804122","Exercise-based Rehabilitation in Patients With Pulmonary Arterial Hypertension","Effects of Exercise-based Rehabilitation on Exercise Capacity, Quality of Life and Physical Activity in Patients With Pulmonary Artery Disease","PAHexercise","Inclusion Criteria:\n\n* Adults over 18 years old residing in Tampere or nearby municipalities.\n* WHO functional classification II-III.\n* Commitment to the exercise program.\n* Stable disease condition with no PAH medication changes in the two months prior.\n* No recent syncope or arrhythmias causing symptoms within the past two months.\n\nExclusion Criteria:\n\n* Severe pulmonary disease or left ventricular failure (HFrEF).\n* Pregnancy.\n* Severe congenital heart defect (Eisenmenger syndrome).\n* Severe liver disease.\n* Acute inflammatory condition.\n* Severe anemia (hemoglobin ≤ 75% of the lower reference limit).\n* Systolic blood pressure below 85 mmHg.\n* Recent syncope.\n* Other significant conditions affecting physical capacity, such as severe neurological diseases or musculoskeletal issues.\n* Untreated severe arrhythmias.\n* Changes in PAH medication during the rehabilitation program.",{"count":58,"type":22},20,"INTERVENTIONAL",[61],"NA","Pulmonary arterial hypertension (PAH) is a rare and severe disease characterized by elevation of pulmonary artery pressure (PAP) and increased pulmonary vascular resistance (PVR) due to the narrowing of small pulmonary arteries. The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) recommend supervised exercise-based rehabilitation as part of the treatment of PAH patients alongside optimal medical therapy (Level of evidence A, Class of recommendation I).\n\nStudies on exercise-based rehabilitation for PAH patients are limited, and most interventions have been conducted at least partially in hospital settings. Unlike more common cardiovascular diseases, there are no detailed international exercise guidelines tailored specifically for PAH patients.\n\nThis study aims to verify that a group-based outpatient rehabilitation protocol suitable for the Finnish healthcare system improves exercise capacity, quality of life, and physical activity of PAH patients and is safe for appropriately selected patients. Additionally, the study aims to determine whether PAH patients adhere to regular exercise training and whether physical activity increases in the long term.\n\nThe goal is to assess whether an outpatient rehabilitation protocol, designed for the Finnish healthcare system, can achieve similar results to those observed in previous international studies. The primary outcome measure is the change in the six-minute walking distance (6MWD) compared to the patient's baseline. Long-term 6MWD data are often available for patients. The 6MWD is the most commonly used primary outcome in randomized and controlled PAH drug trials, and improvements in this test have been the basis for drug approvals. An improvement of 33 meters in the 6MWD is considered clinically significant, and the goal is to achieve this change with group-based outpatient rehabilitation.\n\nSecondary outcomes include changes in quality of life (SF-36), WHO functional class, NT-proBNP levels, echocardiographic parameters, ESC\u002FERS risk-stratification score (four-strata model), muscle strength, respiratory measures, balance, daily step count, and insomnia severity.",[64],"Pulmonary Arterial Hypertension",[64,66,67],"Exercise-based rehabilitation","Intervention","2025-09-03",{"date":70,"type":41},"2025-09-10",{"date":72,"type":41},"2025-01-27",{"date":74,"type":22},"2026-12-31",{"name":47,"class":48},1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":86,"studyType":24,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":76},"100577915","tampere-coronary-artery-disease-and-sudden-cardiac-arrest-study-100577915","NCT06804499","Tampere Coronary Artery Disease and Sudden Cardiac Arrest Study","CADSCA","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. A patient who lives in the area of 'Wellbeing Services County of Pirkanmaa' and seeks treatment for coronary artery disease (CAD).\n3. CAD is diagnosed with invasive coronary angiogram or computed tomography angiogram (CTA) which is evaluated by cardiologists based on current guidelines for stenosis level evaluation and fractional flow reserve (FFR) results.\n4. An invasive coronary angiogram or CTA is done within three (3) months.\n5. Good or moderate everyday functional ability\n\nExclusion Criteria:\n\n1. Life expectancy \\\u003C1 months.\n2. A significant valvular heart disease treated previously (endovascular or surgical) or requires treatment (endovascular or surgical) in the next three (3) months.\n3. Previously implanted cardioverter-defibrillators (ICD) or will be implanted in the next three (3) months.\n4. An active malignancy (ongoing treatment for a solid tumour, metastatic solid tumour, fast progressing haematological malignancy, or equal malignant disease).\n5. A significant neurodegenerative disease (dementia, Mini-Mental State Examination (MMSE) \\\u003C23 or equivalenneurodegenerative disease affecting everyday functional ability, like ALS, myositis, prograded MS-disease or Parkinson's disease).\n6. Intellectual disability or a significant disability affecting cognitive functions\n7. Do-not-resuscitate (DNR) treatment decision\n\nSubgroup with blood samples:\n\nBlood samples are withdrawn from all study subjects under 76 years of age. Additionally, PaxGene samples are withdrawn from i) all study subjects under 65 years of age and ii) subjects between 65-76 years, if they have detected QRS-time\\>110ms in the latest ECG.",{"count":85,"type":22},4000,"15 Years","The goal of this observational study is to recognize clinical and genetic risk factors for sudden cardiac arrest (SCA) and death (SCD) in patients with coronary artery disease (CAD).\n\nThe main questions it aims to answer are:\n\nAre we able to recognize clinical or treatment-related risk factors for SCA or SCD? Can we identify new genetic risk factors for SCA or SCD in patients under 75 years?\n\nParticipants diagnosed with CAD answer a short survey about their medical history and socioeconomic status. A standard ECG addition to a five (5) minute ECG recording is taken from all the study subjects. In addition to a few short physiological tests (e.g. blood pressure, height, weight, grip strength), a blood sample is withdrawn from a selected group of study subjects.\n\nMedical healthcare records are used to follow all study subjects, and no follow-up visits are required.",[28,29,89,27,90],"Sudden Cardiac Death Due to Cardiac Arrhythmia","Acute Coronary Event",[92,93,94,95],"sudden cardiac death","sudden cardiac arrest","coronary artery disease","acute coronary syndrome",{"date":97,"type":41},"2025-02-03",{"date":99,"type":41},"2025-01-13",{"date":101,"type":22},"2042-12-31",{"name":47,"class":48},""]